DoMore Diagnostics welcomes Dr. Lao Saal as our new consulting Medical Director
OSLO – November 26, 2024 – DoMore Diagnostics, a leader in AI and deep-learning precision medicine in cancer, is pleased to announce the appointment of Dr. Lao Saal as our new consulting Medical Director.
Lao holds MD and PhD degrees from Columbia University, is a medical doctor, cancer scientist and entrepreneur focused on advancing cancer research and improving patient outcomes with precision medicine. He currently serves as Associate Professor and Head of Translational Oncogenomics at Lund University, where his research team is aiming to get a better understanding of cancer biology and guide the implementation of research findings and diagnostic innovations into clinical practice.
In 2016, Lao founded SAGA Diagnostics AB, a company that develops cancer biomarkers, particularly circulating tumor DNA, to improve cancer diagnosis and treatment. Lao also provides consulting services in diagnostics, oncology, and health tech, helping to drive innovation in these fields.
CEO and Co-Founder Torbjørn Furuseth, MD, said:
“We are excited to welcome Lao to our growing team! He is an impressive person and with his entrepreneurial mindset combined with his impressive scientific and business background in cancer research and biomarkers, he will be instrumental in advancing our digital biomarker Histotype Px® Colorectal into clinical guidelines and clinical use. Lao’s expertise will play a key role in strengthening our clinical research as we prepare for the commercial launch and clinical implementation.”
“I’m very pleased to be joining the DoMore Diagnostics team. AI applications in digital pathology is a very exciting field, and the Histotype Px® Colorectal algorithm is the leader in colorectal cancer. Accurate prognosis and treatment prediction from a standard H&E slide will make a huge impact in how patients are stratified and improve patient outcomes and quality of life”, added Lao Saal, MD, PhD.
About DoMore Diagnostics
DoMore Diagnostics uses artificial intelligence to make personalized treatment decisions simple and accessible for all cancer patients. Its unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists’ existing workflow. The lead product Histotype Px® Colorectal is a CE-IVDD marked outcome prediction marker for stage II and III colorectal adenocarcinoma that informs the decision of whether to provide adjuvant chemotherapy following surgical resection of the tumor.
About Colorectal Cancer and Histotype Px® Colorectal
Colorectal cancer is the third most common and second most deadly cancer but has seen little innovation in diagnostics and treatment in the last decades. Adjuvant chemotherapy (ACT) may be provided after primary surgery to prevent the disease from recurring, however overtreatment is prevalent with up to 85% of patients with stage II and stage III not benefiting from ACT and only suffering side effects.
Histotype Px® is an advanced deep learning algorithm that analyzes digital histology slides, separating patients into distinct Low, Intermediate and High-risk groups to guide ACT treatment decisions. Data previously published in The Lancet and The Lancet Oncology showed that the test can accurately predict survival outcomes in colorectal cancer patients. Histotype Px® Colorectal was developed to provide clinicians with valuable information to guide personalized treatment decisions and improve patient outcomes.
For more information, please visit:
www.domorediagnostics.com
LinkedIn
The Lancet publication
The Lancet Oncology publication
Contact:
Torbjørn Furuseth, MD
torbjorn.furuseth@domorediagnostics.com